Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Age of patient when antidepressant(s) prescribed:

What condition was this medication prescribed to treat?

What additional medications were you taking at the time?

Did patient hurt themselves during or after taking the drug?

Did patient become violent during or after taking the drug?

Was suicide attempted?

Was hospitalization or institutionalization required after taking antidepressant(s)?

Did loved one commit suicide?

If patient did attempt or commit suicide, did patient ever attempt suicide previously?

If patient did commit suicide, what was the method of suicide?

Please describe violent or suicidal behavior:

If you ever tried to stop taking Paxil and experienced withdrawal, please describe the withdrawal side effects:

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

New York AG Files Suit Against GlaxoSmithKline

Jun 2, 2004 | Raleigh Triangle Business Journal

The New York Attorney General's Office filed suit Wednesday against GlaxoSmithKline, alleging that the pharmaceutical giant concealed efficacy and safety issues concerning the use of the company's antidepressant medication Paxil in children.

Based in London, GlaxoSmithKline has co-U.S. headquarters in Philadelphia and Research Triangle Park, where the company has 4,000 employees.

The lawsuit, filed by New York Attorney General Eliot Spitzer at New York State Supreme Court, alleges that GlaxoSmithKline failed to disclose study data in some clinical trials that suggested the use of Paxil may have contributed to a higher rate of suicidal thoughts in children.

GlaxoSmithKline officials said they had not seen the lawsuit and could not comment on its contents.

The Food and Drug Administration began re-examining clinical data reports this year following growing concerns about the use of antidepressants in children.

Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo